Abstract
Background Continuous Glucose Monitoring (CGM) systems have revolutionized diabetes management by providing real-time blood glucose tracking. However, there is a need for openly accessible tools that can analyze CGM data in relation to specific events like meals or exercise, which often require extensive technical skills to interpret, thus restricting its broader use among researchers and clinicians. Developing user-friendly web applications to facilitate this analysis could significantly broaden accessibility and utility.
Method Diametrics was built with a focus on ease-of-use and versatility. The application’s efficacy was validated against iglu, an established R tool with a no-code web app for CGM analysis, using data from 418 participants from three studies. The unique period-specific analysis feature was demonstrated through an illustrative case study.
Results Diametrics proved effective at replicated established CGM metrics, demonstrating high concordance with iglu. The platform supports a wide range of CGM devices, accommodates data in various formats, and offers extensive customization in the analysis settings. The case study highlighted Diametrics’ ability to integrate exercise-related data with CGM readings, enabling detailed analyses of how different exercise types, intensities, and times of day impact glucose levels.
Conclusions Diametrics is a freely available, reproducible, user-friendly, and accurate web-based tool for CGM data analysis with a unique capability to analyze data over specific time periods. With its intuitive design and open-source accessibility, Diametrics provides a valuable resource in diabetes research and management, empowering users of various technical levels to perform complex analyses with ease.
Competing Interest Statement
M.J.A. receives research funding from the National Institute for Health Research (NIHR) Applied Research Collaboration, South West Peninsula. C.L.R.'s PhD is supported by the Expanding Excellence in England (E3) fund. R.C.A. has received remuneration from Novo Nordisk, AstraZeneca, and Eli Lilly for conducting educational talks on diet and exercise for healthcare professionals. Funding and support was provided by the Royal Academy of Engineering (RAEng), London, UK, through a research fellowship in medical AI to N.V.
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
T1-DEXI & T1-DEXIP: These studies were accessed through Vivli, Inc. These studies have been conducted with ethical approval from their respective institutional review boards. Access to this data via Vivli was granted under the condition that the original ethical approvals encompass the secondary use of data for research purposes. This ensures that our use of these datasets adheres to the established ethical standards set forth by the original research protocols. MOTIVATE-T2D Study: Ethics committee/IRB of Liverpool John Moore University gave ethical approval for the original study, and this approval extends to the secondary use of de-identified data for the validation of the Diametrics app. EXTOD Study: Ethics committee/IRB of University of Birmingham gave ethical approval for the original study, and this approval extends to the secondary use of de-identified data for the validation of the Diametrics app.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
m.allen{at}exeter.ac.uk, M.Saunby{at}exeter.ac.uk, r.pulsford{at}exeter.ac.uk, n.vaughan{at}exeter.ac.uk, m.s.cocks{at}ljmu.ac.uk, jllow{at}mail.ubc.ca, K.L.Hesketh{at}bham.ac.uk, R.C.Andrews{at}exeter.ac.uk
Data Availability
This study is based on research using data from the Type 1 Diabetes EXercise Initiative (T1-DEXI) and Type 1 Diabetes EXercise Initiative Pediatric (T1-DEXIP) studies that has been made available through Vivli, Inc. The MOTIVATE and EXTOD datasets are not currently available for public access.
Abbreviations
- ADA
- American Diabetes Association
- AUC
- Area Under the Curve
- CGM
- Continuous Glucose Monitoring
- EXTOD
- Exercise in Type 1 Diabetes
- JCHR
- Jaeb Center for Health Research
- MOTIVATE-T2D
- Mobile Health Biometrics to Enhance Exercise and Physical Activity Adherence in Type 2 Diabetes
- T1-DEXI
- Type 1 Diabetes EXercise Initiative
- T1-DEXIP
- Type 1 Diabetes EXercise Initiative Pediatric
